NSE: ZYDUSLIFE | BSE: 532321

Mid-range Performer

Download real time

942.50 5.25 (0.56%)

966.4K NSE+BSE Volume

NSE 28 Nov, 2025 3:31 PM (IST)

94,837.6

Market Cap

High in industry

Beta 1Year

Low volatility

US FDA Approval

Zydus Life gets US FDA nod for Empagliflozin & Linagliptin tablets with a market size of $215.8 mn See details

Zydus Lifesciences Ltd. share price target and research reports

Latest analyst research reports with target prices and PDF download for ZYDUSLIFE, BSE:532321 Zydus Lifesciences Ltd.

Search Inside the pdf :

Zydus Lifesciences Ltd.

07 Nov 2025

942.50

0.56%

Strong domestic and international growth offset US softness; margins moderated amid higher costs

Buy: Zydus Lifesciences Ltd.

Target

Deven Choksey

We remain constructive on Zydus Lifesciences given its improving business mix, continued progress on complex launches, and stable performance in India formulations.

Number of FII/FPI investors increased from 697 to 707 in Sep 2025 qtr.

Zydus Lifesciences Ltd.

07 Nov 2025

942.50

0.56%

Zydus Lifesciences (ZYDUSLIF IN) Q2FY26 Result Update US...

Accumulate: Zydus Lifesciences Ltd.

Target

Prabhudas Lilladhar

Zydus Lifesciences L.. has an average target of 1040.50 from 4 brokers.

Zydus Lifesciences Ltd.

07 Nov 2025

942.50

0.56%

Limited visibility in US beyond current exclusivities

Hold: Zydus Lifesciences Ltd.

Target

ICICI Securities Limited

Zydus Lifesciences’ (Zydus) recent acquisitions in consumer wellness and medtech divisions helped it in driving a beat in Q2FY26 revenue though subdued margins of these businesses and lower revenue of gRevlimid dragged EBITDA margin (down 28bps YoY and 426bps QoQ).

Zydus Lifesciences Ltd. is trading below all available SMAs

Zydus Lifesciences Ltd.

03 Sep 2025

942.50

0.56%

ZYDUS LIFESCIENCES LIMITED

Buy: Zydus Lifesciences Ltd.

Target

Geojit BNP Paribas

*over or under performance to benchmark index Zydus Lifesciences Ltd (Zydus) is one of India's leading, vertically integrated pharmaceutical companies. It operates across the value chain, from manufacturing finished dosages to active pharmaceutical ingredients, as well as animal healthcare and wellness products. Zydus' revenue increased 5.9% YoY to Rs. 6,574cr in Q1FY26 driven by 6.5% YoY...

Zydus Lifesciences Ltd. is trading below all available SMAs

Zydus Lifesciences Ltd.

25 Aug 2025

942.50

0.56%

Q1FY26 performance stood stable amid slower traction in US offset by new product launches

Buy: Zydus Lifesciences Ltd.

Target

Deven Choksey

We have revised our FY26E/FY27E EPS estimates by +2.6%/-7.4% as we bake in slower revenue growth as Revlimid and Mirabegron sales is expected to taper-off and factor in a marginal increase in EBITDA margins in FY26, while we factor in weaker margins on the back of changing product mix towards competitive generics over FY27.

Zydus Lifesciences L.. has an average target of 1040.50 from 4 brokers.

Zydus Lifesciences Ltd.

13 Aug 2025

942.50

0.56%

Momentum may fizzle out on loss of exclusivities

Hold: Zydus Lifesciences Ltd.

ICICI Securities Limited

Zydus Lifesciences (Zydus)’s Q1FY26 print beat our expectations, though its revenue grew a mere 5.9% while EBITDA/PAT shrunk 3.3%/0.7% YoY. US biz sales were flat YoY.

Number of FII/FPI investors increased from 697 to 707 in Sep 2025 qtr.

Zydus Lifesciences Ltd.

13 Aug 2025

942.50

0.56%

Zydus Lifesciences (ZYDUSLIF IN) Q1FY26 Result Update Higher...

Accumulate: Zydus Lifesciences Ltd.

Prabhudas Lilladhar

Zydus Lifesciences (ZYDUSLIF) Q1 EBITDA beat our estimates by 5%. We believe gRevlimid + gMirabegron contributes +45% to total FY25/Q1FY26 EPS which will see erosion from H2FY26. Though, company is working on a robust pipeline of complex products, including injectables, 505(b)2, transdermals, NCE, biosimilars and vaccines, they are expected to materialize over the next 23 years. We expect US sales to decline in FY27 given sales erosion in some of...

Zydus Lifesciences Ltd. is trading below all available SMAs

Zydus Lifesciences Ltd.

25 Jul 2025

942.50

0.56%

Stock Flash

Buy: Zydus Lifesciences Ltd.

Deven Choksey

Zydus Lifesciences Ltd has received tentative approval from the United States Food and Drug Administration (USFDA) for its Ibrutinib tablets in 140 mg, 280 mg, and 420 mg strengths.

Zydus Lifesciences L.. has an average target of 1040.50 from 4 brokers.

Zydus Lifesciences Ltd.

21 May 2025

942.50

0.56%

Zydus Lifesciences (ZYDUSLIF IN) Q4FY25 Result Update High...

Accumulate: Zydus Lifesciences Ltd.

Target

Prabhudas Lilladhar

Zydus Lifesciences (ZYDUSLIF) Q4 EBITDA including other operating income beat our estimates by 8%. We believe gRevlimid + gMirabegron contributes +45% to total FY25E EPS which will see erosion from FY27. Though, company is working on a robust pipeline of complex products, including injectables, 505(b)2, transdermals, NCE, biosimilars and vaccines, they are expected to materialize over the next 23 years. We expect US sales to decline in FY27...

Zydus Lifesciences Ltd. is trading below all available SMAs

Zydus Lifesciences Ltd.

21 May 2025

942.50

0.56%

Headwinds in US to curtail margins

Hold: Zydus Lifesciences Ltd.

Target

ICICI Securities Limited

Zydus Lifesciences’ (Zydus) Q4FY25 revenue gained with healthy traction in US (+20%), domestic branded formulation (+10.7%) and its consumer business (+17.1%).

Zydus Lifesciences Ltd. is trading below all available SMAs

Is Cadila Healthcare Ltd. worth buying?

864 Votes:

Buy 81.94%

Sell 9.95%

Hold 8.1%

RESEARCH REPORTS

Accumulate SEE REPORTS >

pdf

Buy SEE REPORTS >

pdf